https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49803 38 years (1.34; 1.04–1.73); those with disease duration > 7 years (1.33; 1.01–1.74); those with EDSS score < 6 (1.21; 1.01–1.46) and ≥ 6 (1.93; 1.11–3.34); and patients with no new MRI lesion (1.73; 1.19–2.51). Conclusions: Overall, in women, younger patients, those with shorter disease durations, and patients with pre-treatment relapses, natalizumab was associated with a lower frequency of multiple sclerosis relapses than fingolimod. It was also associated with an increased chance of recovery from disability among most patients, particularly women and those with no recent MRI activity.]]> Wed 31 May 2023 15:59:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54209 Wed 28 Feb 2024 16:36:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52719 Wed 28 Feb 2024 16:25:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51451 3 seconds on CTP. Regression analyses were used to identify clinical and imaging variables that predicted poor functional outcome. Results: A total of 139 patients with mild stroke were included, of whom 27 (19%) had poor functional outcome. Patients with poor outcome, compared with those with good outcome, had much larger perfusion lesion volume (median 80 mL vs 41 mL, p < 0.001). Perfusion lesion was a significant predictor of poor outcome in either univariable regression (crude OR = 1.02, 95% CI = [1.01-1.03]) or multivariable regression model (adjusted OR = 1.01, 95% CI = [1.01-1.02]), adjusting for occlusion site, good collaterals, baseline stroke severity, age, IV thrombolysis (IVT), and onset to scan time. A perfusion lesion of 65 mL was the optimal cutpoint to identify poor functional outcome (sensitivity = 59%, specificity = 77%). Patients with perfusion lesion ≥65 mL, compared with patients with perfusion lesion <65 mL, showed a much higher rate of poor functional outcome (38% vs 11%, p < 0.001). Of the 139 patients in this study, 95 received IVT. Patients treated with or without IVT did not influence their outcomes (crude OR = 0.74, 95% CI = [0.31-1.78]). Discussion: A perfusion lesion of ≥65 mL predicted poor functional outcome in mild stroke patients with LVO.]]> Wed 28 Feb 2024 15:56:25 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50276 Wed 28 Feb 2024 15:44:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50584 Wed 28 Feb 2024 15:06:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52044 Wed 27 Sep 2023 10:07:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44977 Wed 26 Oct 2022 08:54:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50481  1,000 U/L). The Australian Toxicology Monitoring (ATOM) study is a prospective observational study, recruiting via two poison information centers and four toxicology units. Patients following an acute APAP ingestion presenting < 24 hours post-ingestion were recruited. Initial samples were analyzed for APAP metabolites, those measured were the nontoxic glucuronide (APAP-Glu) and sulfate (APAP-Sul) conjugates and NAPQI (toxic metabolite) conjugates APAP-cysteine (APAP-Cys) and APAP-mercapturate (APAP-Mer). The primary outcome was hepatotoxicity. In this study, 200 patients were included, with a median ingested dose of 20 g, 191 received acetylcysteine at median time of 5.8 hours post-ingestion. Twenty-six patients developed hepatotoxicity, one had hepatotoxicity on arrival (excluded from analysis). Those who developed hepatotoxicity had significantly higher total CYP metabolite concentrations: (36.8 μmol/L interquartile range (IQR): 27.8-51.7 vs. 10.8 μmol/L IQR: 6.9-19.5) and these were a greater proportion of total metabolites (5.4%, IQR: 3.8-7.7) vs. 1.7%, IQR: 1.3-2.6, P < 0.001)]. Furthermore, those who developed hepatotoxicity had lower APAP-Sul concentrations (49.1 μmol/L, IQR: 24.7-72.2 vs. 78.7 μmol/L, IQR: 53.6-116.4) and lower percentage of APAP-Sul (6.3%, IQR: 4.6-10.9 vs. 13.1%, IQR, 9.1-20.8, P < 0.001)]. This study found that those who developed hepatotoxicity had higher APAP metabolites derived from CYP pathway and lower sulfation metabolite on presentation. APAP metabolites may be utilized in the future to identify patients who could benefit from increased acetylcysteine or newer adjunct or research therapies.]]> Wed 26 Jul 2023 18:22:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25861 Wed 25 Jan 2017 12:06:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34855 Wed 24 May 2023 12:20:01 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34945 Wed 23 Feb 2022 16:05:28 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33561 Wed 21 Nov 2018 09:47:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47181 1 As of 26 April 2020, it has infected over three million people worldwide and caused more than 200 000 deaths.² Chronic liver diseases from HCV, HBV, alcoholism or non-alcoholic fatty liver disease (NAFLD) represent a major disease burden in the world. Around 1.5 billion people have chronic liver diseases worldwide, and it causes around two million deaths per year. While self-resolving elevations of transaminases are reported in 15%–54% of patients with COVID-19, those with more severe disease experience worse liver injury.^3–5 An open international registry, SECURE-Cirrhosis, is reporting a mortality rate of 40% among the 118 patients with cirrhosis.⁶ Thus, patients with chronic liver disease represent a vulnerable population who are at higher risk of acquiring COVID-19 and suffering from its complications.^{7 8}]]> Wed 14 Dec 2022 15:56:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39131 Wed 13 Mar 2024 14:30:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52453 Wed 11 Oct 2023 15:07:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15866 Wed 11 Apr 2018 17:31:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29208 Wed 11 Apr 2018 16:44:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21161 Daboia russelii) envenoming in Sri Lanka. All patients received Indian F(ab’)₂ snake antivenom manufactured by VINS Bioproducts Ltd. Antivenom concentrations were measured with sandwich enzyme immunoassays. Timed antivenom concentrations were analysed using MONOLIXvs4.2. One, two and three compartment models with zero order input and first order elimination kinetics were assessed. Models were parameterized with clearance(CL), intercompartmental clearance(Q), central compartment volume(V) and peripheral compartment volume(V_P). Between-subject-variability (BSV) on relative bioavailability (F) was included to account for dose variations. Covariates effects (age, sex, weight, antivenom batch, pre-antivenom concentrations) were explored by visual inspection and in model building. There were 75 patients, median age 57 years (40-70y) and 64 (85%) were male. 411 antivenom concentration data points were analysed. A two compartment model with zero order input, linear elimination kinetics and a combined error model best described the data. Inclusion of BSV on F and weight as a covariate on V improved the model. Inclusion of pre-antivenom concentrations or different batches on BSV of F did not. Final model parameter estimates were CL,0.078 Lh⁻¹, V,2.2L, Q,0.178Lh⁻¹ and V_P,8.33L. The median half-life of distribution was 4.6h (10-90%iles:2.6-7.1h) and half-life of elimination, 140h (10^th-90^th percentilesx:95-223h). Conclusion: Indian F(ab’)₂ snake antivenom displayed biexponential disposition pharmacokinetics, with a rapid distribution half-life and more prolonged elimination half-life.]]> Wed 11 Apr 2018 16:20:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20993 Wed 11 Apr 2018 15:59:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25641 Wed 11 Apr 2018 15:12:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27198 Wed 11 Apr 2018 14:24:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19506 Wed 11 Apr 2018 11:23:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:29012 Wed 11 Apr 2018 09:36:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55109 Wed 10 Apr 2024 08:53:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:44516 95% of fractions were successfully delivered. The secondary outcomes were (1) the improvement in beam-target geometric alignment, (2) the improvement in dosimetric coverage of the prostate and avoidance of critical structures, and (3) no acute grade ≥3 genitourinary or gastrointestinal toxicity. Results: All 858 planned fractions were successfully delivered with MLC tracking, demonstrating the primary outcome of feasibility (P < .001). MLC tracking improved the beam-target geometric alignment from 1.4 to 0.90 mm (root-mean-square error). MLC tracking improved the dosimetric coverage of the prostate and reduced the daily variation in dose to critical structures. No acute grade ≥3 genitourinary or gastrointestinal toxicity was observed. Conclusions: Electromagnetic-guided MLC tracking radiation therapy for prostate cancer is feasible. The patients received improved geometric targeting and delivered dose distributions that were closer to those planned than they would have received without electromagnetic-guided MLC tracking. No significant acute toxicity was observed.]]> Wed 09 Nov 2022 10:02:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32040 Wed 09 Feb 2022 15:55:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50856 Wed 09 Aug 2023 10:06:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50852 18y) from the Anuradhapura snakebite cohort were reviewed: Group I had a snakebite during August 2013-October 2014 and was reviewed after 4 years, and group II had a snakebite during May 2017-August 2018, and was reviewed after one year. Patients were invited by telephone, by sending let-ters, or doing home visits, including 199 of 736 patients (27%) discharged alive from group I and 168 of 438 patients (38%) from group II, a total of 367 followed up. Health effects were categorised as musculoskeletal, impact on daily life, and medically unexplained. Health issues were attributed to snakebite in 107/199 patients (54%) from group I and 55/168 patients (33%) from group II, suggesting the proportion with health issues increases with time. Sixteen patients (all viperine bites) had permanent musculoskeletal problems, none with a significant functional disability affecting daily routine. 217/367 reported being more vigilant about snakes while working outdoors, but only 21/367 were using protective foot-wear at review. Of 275 farmers reviewed, only six (2%) had restricted farming activities due to fear of snakebite, and only one stopped farming. 104/199 (52%) of group I and 42/168 (25%) of group II attributed non-specific symptoms (fatigue, body aches, pain, visual impairment) and/or oral cavity-related symptoms (avulsed teeth, loose teeth, receding gums) to the snakebite, which cannot be explained medically. In multivariate logistic regres-sion, farming, type of snake, antivenom administration, and time since snakebite were associated with medically unexplained symptoms. The latter suggests medically unexplained effects increased with time. Based on two groups of snakebite patients reviewed one and four years post-bite, we show that long-term musculoskeletal disabilities are uncommon and not severe in snakebite survivors in rural Sri Lanka. However, a large portion of patients complain of various non-specific general and oral symptoms, not explainable based on the known pathophysiology of snakebite. These perceived effects of snakebite were more common in patients with systemic envenoming, and were more frequent the longer the time post-bite.]]> Wed 09 Aug 2023 09:45:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50847 Wed 09 Aug 2023 09:32:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36083 Wed 05 Feb 2020 13:13:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34445 1 episode. Safety data revealed no new adverse events. Conclusion: Mesalazine was not superior to placebo in preventing recurrence of diverticulitis.]]> Wed 04 Sep 2019 09:56:16 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52188  100.000/mm3 [n = 99 (57.9%)] and prothrombin time (PT)/activated partial thromboplastin time (aPTT) < 1.5 times the normal control [n = 85 (49.7%)] in patients needing spinal surgery. MRI [n = 160 (93.6%)] and spinal surgery [n = 158 (92.4%)] should be performed after intracranial, hemodynamic, and respiratory stabilization by most respondents. Corticosteroids [n = 103 (60.2%)], ISP/SCPP monitoring [n = 148 (86.5%)], and therapeutic hypothermia [n = 137 (80%)] were not utilized by most respondents. Conclusions: Our survey has shown a great worldwide variability in clinical practices for acute phase management of tSCI patients with polytrauma. These findings can be helpful to define future research in order to optimize the care of patients suffering tSCI.]]> Wed 04 Oct 2023 11:09:50 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55022 Wed 03 Apr 2024 15:28:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50684 Wed 01 May 2024 15:04:24 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51151 Tue 29 Aug 2023 09:12:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47197 χ² analysis. Results: From 5 centers, 1,407 patients were included in this study; of these, 282 had HT. The cohort was split into a derivation cohort (1,025, 70% patients) and a validation cohort (382 patients or 30%). The extraction fraction (E) permeability map at a threshold of 30% relative to contralateral had the highest AUC at predicting any HT (derivation AUC 0.85, 95% confidence interval [CI], 0.79–0.91; validation AUC 0.84, 95% CI 0.77–0.91). The AUC improved when permeability was assessed within the acute perfusion lesion for the E maps at a threshold of 30% (derivation AUC 0.91, 95% CI 0.86–0.95; validation AUC 0.89, 95% CI 0.86–0.95). Previously proposed associations with HT and parenchymal hematoma showed lower AUC values than the permeability measure. Interpretation: In this large multicenter study, we have validated a highly accurate measure of HT prediction. This measure might be useful in clinical practice to predict hemorrhagic transformation in ischemic stroke patients before receiving alteplase alone.]]> Tue 28 Mar 2023 08:14:38 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54477 Tue 27 Feb 2024 14:56:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54430 Tue 27 Feb 2024 13:58:29 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43418 Tue 20 Sep 2022 08:26:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47256 Tue 17 Jan 2023 12:30:39 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46364 Tue 15 Nov 2022 15:09:02 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43104 15 mL, and a total hypoperfused volume:core volume ratio of >1.8. The primary outcome was good functional outcome at 90 days (modified Rankin Scale score, 0-2).CTP was acquired in 138 of 316 ESCAPE patients. Penumbral patterns were present in 116 of 128 (90.6%) of patients with interpretable CTP data. The rate of good functional outcome in penumbral pattern patients (53 of 114; 46%) was higher than that in nonpenumbral patients (2 of 12; 17%; P=0.041). In penumbral patients, endovascular therapy increased the likelihood of a good clinical outcome (34 of 58; 57%) compared with those in the control group (19 of 58; 33%; odds ratio, 2.68; 95% confidence interval, 1.25-5.76; P=0.011). Only 3 of 12 nonpenumbral patients were randomized to the endovascular group, preventing an analysis of treatment effect.The majority of patients with CTP imaging in the ESCAPE trial had penumbral patterns, which were associated with better outcomes overall. Patients with penumbra treated with endovascular therapy had the greatest odds of good functional outcome. Nonpenumbral patients were much less likely to achieve good outcomes.]]> Tue 13 Sep 2022 12:47:32 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54232 Tue 13 Feb 2024 12:28:05 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35045 Tue 11 Jun 2019 15:15:58 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54164 Tue 06 Feb 2024 14:02:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51452 2) were modeled within purpose-built Bayesian linear and logistic regression frameworks. Interaction effects between stroke lesions and a high vs low WMH burden were integrated via hierarchical model structures. Models were adjusted for age, age2, sex, total DWI lesion and WMH volumes, and comorbidities. Data were split into derivation and validation cohorts. Results: A total of 928 patients with AIS contributed to acute stroke severity analyses (age: 64.8 [14.5] years, 40% women) and 698 patients to long-term functional outcome analyses (age: 65.9 [14.7] years, 41% women). Stroke severity was mainly explained by lesions focused on bilateral subcortical and left hemispherically pronounced cortical regions across patients with both a high and low WMH burden. Lesions centered on left-hemispheric insular, opercular, and inferior frontal regions and lesions affecting right-hemispheric temporoparietal regions had more pronounced effects on stroke severity in case of high compared with low WMH burden. Unfavorable outcomes were predominantly explained by lesions in bilateral subcortical regions. In difference to the lesion location–specific WMH effects on stroke severity, higher WMH burden increased the odds of unfavorable outcomes independent of lesion location. Discussion: Higher WMH burden may be associated with an increased stroke severity in case of stroke lesions involving left-hemispheric insular, opercular, and inferior frontal regions (potentially linked to language functions) and right-hemispheric temporoparietal regions (potentially linked to attention). Our findings suggest that patients with specific constellations of WMH burden and lesion locations may have greater benefits from acute recanalization treatments. Future clinical studies are warranted to systematically assess this assumption and guide more tailored treatment decisions.]]> Tue 05 Sep 2023 18:01:19 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51437 Tue 05 Sep 2023 17:56:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40149 v 45.9%), the proportion of patients who died in hospital was lower (0.3% v 1.4%), and re-admission within 28 days was less frequent (2.3% v 3.6%). The 50 DRGs with greatest HIH activity encompassed 65 811 HIH admissions (82.1%), or 8.4% (95% CI, 8.4–8.5%) of all admissions in these DRGs. HIH admission numbers grew more rapidly than non-HIH admissions, but the difference was not statistically significant. Conclusions: HIH care is most frequently provided to patients requiring hospital treatment related to infections, venous thromboembolism, or post-surgical care. Its use could be expanded in clinical areas where it is currently used, and extended to others where it is not. HIH activity is growing. It should be systematically monitored and reported to allow better overview of its use and outcomes.]]> Tue 05 Jul 2022 15:56:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34917 Tue 03 Sep 2019 18:18:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34431 Tue 03 Sep 2019 17:59:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39190 Thu 26 May 2022 15:26:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42135 Thu 18 Aug 2022 16:06:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45457 Thu 17 Aug 2023 11:09:33 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54270 Thu 15 Feb 2024 14:31:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50899 Thu 10 Aug 2023 13:18:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50316 Thu 03 Aug 2023 09:41:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28626 Thu 01 Jun 2023 18:00:10 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20827 N = 82), while controls comprised the next available admission, matched for age and gender (N = 82). The prototypical patient was a young, single male, with a diagnosis of schizophrenia, a history of substance use and previous psychiatric admissions. The majority of cases had a history of aggression and recent offences against public order. They also revealed a higher likelihood of involvement in 'less serious' aggressive incidents (e.g. verbal threats or demands) during the index admission. Clinically, knowledge of each patient's recent offence history, arrival mode and observed characteristics on admission (including any verbal aggression) may be important in the management of subsequent inpatient aggression.]]> Sat 24 Mar 2018 08:05:53 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20771 vs as-needed 1·05, 0·92–1·20). We recorded no difference between treatment groups for time to recovery (adjusted p=0·79). Adherence to regular tablets (median tablets consumed per participant per day of maximum 6; 4·0 [IQR 1·6–5·7] in the regular group, 3·9 [1·5–5·6] in the as-needed group, and 4·0 [1·5–5·7] in the placebo group), and number of participants reporting adverse events (99 [18·5%] in the regular group, 99 [18·7%] in the as-needed group, and 98 [18·5%] in the placebo group) were similar between groups. Interpretation: Our findings suggest that regular or as-needed dosing with paracetamol does not affect recovery time compared with placebo in low-back pain, and question the universal endorsement of paracetamol in this patient group.]]> Sat 24 Mar 2018 08:00:22 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19431 Sat 24 Mar 2018 07:51:57 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26274 Sat 24 Mar 2018 07:40:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25927 Sat 24 Mar 2018 07:27:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30177 P _Trend < .001). Conclusions: COPD and PLOS are 2 of many factors that affect long-term mortality in postoperative CABG patients. Aggressive treatment strategies aimed at early weaning off of mechanical ventilation and prevention of reintubation among COPD patients must be considered carefully as a means to reduce length of stay after CABG. Our results also have important implications for the long-term management of these patients and strategies for containing costs over the life course of the patient.]]> Sat 24 Mar 2018 07:26:16 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24683 Sat 24 Mar 2018 07:10:55 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55798 23.7% risk of incident N1b disease). Conclusions: A small number of PTMCs may recur, and the presence of involved lymph nodes at diagnosis is a predictive factor. In this study, the presence of N1b disease at diagnosis was the strongest predictor of future recurrence. However, N1a disease, especially with >5 involved N1a nodes, was also predictive.]]> Sat 22 Jun 2024 12:47:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55797 Sat 22 Jun 2024 12:46:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48172 Sat 11 Mar 2023 12:23:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32848 Mon 23 Sep 2019 12:46:39 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:32143 Mon 23 Sep 2019 10:21:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52705 Mon 23 Oct 2023 16:04:10 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40094 Mon 20 Nov 2023 16:00:56 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51771 Mon 18 Sep 2023 14:29:54 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39140 Mon 16 May 2022 15:34:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46218 Mon 14 Nov 2022 12:12:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46198 2 days 1 to 3, and etoposide 80 mg/m² days 1 to 3 (R-IE) every 21 days for 6 cycles plus 2 doses of rituximab. Revised international prognostic index 3–4 was seen in 53% and prior rituximab exposure in 60%. The complete and overall response rates were 55% and 76%, respectively. Median progression free survival (PFS) and overall survival were 23 and 24 months, respectively. Patients relapsing within 12 months of prior treatment had a median PFS of 2.5 months compared to 23 months for those relapsing beyond 12 months. Grade 3–4 thrombocytopenia and neutropenia occurred in one and eight patients, respectively. R-IE is an effective, well tolerated regimen in RR-DLBCL patients not fit for autoSCT.]]> Mon 14 Nov 2022 11:22:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51582 Mon 11 Sep 2023 14:36:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51567 Mon 11 Sep 2023 14:22:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55072 Mon 08 Apr 2024 14:03:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50755 Mon 07 Aug 2023 15:25:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36221 Mon 06 Apr 2020 10:08:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46879 Mon 05 Dec 2022 14:09:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:53522 18, and a treatment plan that included transfer from methadone to buprenorphine. Data were extracted on methadone dose, transfer medications, time to buprenorphine initiation, and transfer outcome. Interventions: Subjects were transferred via two methods: morphine bridged and nonbridged. Main outcome measure: The primary outcome measure was successful transition to buprenorphine. Results: Seventy-one subjects met inclusion criteria, of whom 62 initiated buprenorphine and 53 discharged on buprenorphine. Longer delay to buprenorphine initiation was seen with higher methadone doses. The highest daily methadone dose in subjects completing transfer was 180 mg. Outcomes with morphine bridging, using a steady state methadone: morphine ratio of 1:4, were similar to direct transfer. Only one subject discontinued buprenorphine because of PW. Conclusions: Transfer from high doses of methadone to buprenorphine can be achieved with high success rates in the in-patient setting.]]> Mon 04 Dec 2023 09:33:33 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41260 Mon 01 Aug 2022 09:21:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49675 Fri 26 May 2023 16:24:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51230 15 mL/h) and slow (≤15 mL/h), based on its interaction with bridging IVT in predicting the primary outcome. The primary outcome was modified Rankin scale of 0-2 at 3 months. The secondary outcomes included successful thrombectomy reperfusion defined by modified Thrombolysis in Cerebral Infarction score of 2b-3 and time from groin puncture to reperfusion. Results: Of the 1,221 EVT patients in the INSPIRE, 323 patients were selected, of which 82 patients received direct EVT and 241 patients received bridging IVT. Bridging IVT was associated with a higher rate of good clinical outcome among patients with fast core growth (39% vs 7% for direct EVT, odds ratio [OR] 8.75 [1.96-39.1], p = 0.005), but the difference was not notable for patients with slow core growth (55% vs 55% for direct EVT, OR 1.00 [0.53-1.87], p = 0.989). In patients with fast core growth, the bridging and direct EVT patients showed no difference in the reperfusion rate (80% vs 76%, p = 0.616). However, patients who received bridging IVT were more likely to achieve reperfusion earlier (the median groin to reperfusion time of 63.0 vs 94.0 minutes, p = 0.005). Discussion: Patients with fast core growth were more likely to benefit from bridging IVT. This is likely because prior IVT facilitates clot removal and thus reduces time to reperfusion.]]> Fri 25 Aug 2023 13:18:37 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54924 Fri 22 Mar 2024 09:32:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40118 Fri 22 Jul 2022 13:48:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40030 Fri 22 Jul 2022 13:07:48 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51684 Fri 15 Sep 2023 09:37:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51682 Fri 15 Sep 2023 09:35:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47319 70mL. We aimed to compare outcomes of EVT and non-EVT patients with an ischemic core≥70mL, hypothesizing that there would be a benefit from EVT for fair outcome (three-month modified Rankin Scale, mRS, 0-3) after stroke. METHODS: Retrospective analysis of patients enrolled into a multi-center (Australia, China and Canada) registry (2012-2020) who underwent CTP within 24 hours of stroke onset and had a baseline ischemic core≥70mL. Primary outcome was the estimation of the association of EVT in patients with core volume ≥70mL, as well as within 70-100mL and ≥100mL subgroups with fair outcome. RESULTS: Of the 3283 patients in the registry, 299 had CTP core≥70 mL and 269 complete data (135 had core volume between 70-100mL and 134≥100mL). EVT was performed in 121(45%) patients. EVT-treated patients were younger (median 69 versus 75 years; p=0.011), had lower pre-stroke mRS, and smaller median core volumes, 92[79-116.5]mL versus 105.5[85.75-138]mL, (p=0.004). EVT-treated patients had higher odds of achieving fair outcome in adjusted analysis (30% versus 13.9% in the non-EVT group; aOR 2.1(95% CI 1, 4.2), p=0.038). The benefit was seen predominantly in those with 70-100mL core (71 /135 (52.6%) EVT-treated), with 54.3% in EVT-treated versus 21% in non-EVT group achieving a fair outcome (aOR 2.5 (95% CI 1, 6.2), p=0.005). Of those with a core≥100mL, 50 /134(37.3%) underwent EVT. Proportions of fair outcome were very low in both groups (8.1% versus 8.7%; p=0.908). DISCUSSION: We found a positive association of EVT with 3-month outcome after stroke in patients with a baseline CTP ischemic core volume 70-100 mL but not in those with ≥100 mL. Randomized data to confirm these findings is required. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that EVT is associated with better motor outcomes 3 months following CTP-defined ischemic stroke with core of 70-100 mL.]]> Fri 13 Jan 2023 11:06:45 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46168 Fri 11 Nov 2022 19:54:47 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46110 Fri 11 Nov 2022 15:37:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46130 Fri 11 Nov 2022 15:21:48 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34896 0.05). Our findings suggest that when making cancer treatment decisions, clinicians should consider offering patients and support persons written and online information, combined with two shorter consultations.]]> Fri 10 Mar 2023 17:39:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26667 Fri 10 Mar 2023 17:32:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51559 Fri 08 Sep 2023 16:29:26 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:41586 Fri 05 Aug 2022 14:51:46 AEST ]]>